Results 41 to 50 of about 47,298 (270)

MuSK (Muscle Specific Kinase) positive myasthenia: Grave prognosis or undue prejudice?

open access: yesAnnals of Indian Academy of Neurology, 2020
Objectives: Patients with muscle-specific kinase (MuSK)-positive myasthenia are generally considered to have a grave prognosis. We present our experience of patients with myasthenia with different antibody status. This is followed by a short discourse on
Priyanka Samal   +3 more
doaj   +1 more source

Autoantigen mRNA‐LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity

open access: yesAdvanced Science, EarlyView.
Systemic and intramuscular delivery of autoantigen mRNA via lipid nanoparticles reprograms antigen‐presenting cells toward a mature, homeostatic state, driving antigen‐specific T cell exhaustion and providing therapeutic efficacy across autoimmune disease models.
Paulien Baeten   +30 more
wiley   +1 more source

Methylprednisolone pulse versus docetaxel in recurrent thymoma with myasthenia gravis

open access: yesFrontiers in Neurology
IntroductionThis study aims to compare the effectiveness and safety of methylprednisolone pulse versus docetaxel in treating recurrent thymoma with myasthenia gravis (MG).MethodsWe conducted a single-center, open-label, retrospective study that included ...
Hongxia Yang   +9 more
doaj   +1 more source

A nurse-led nomogram for predicting the risk of myasthenic crisis in patients with myasthenia gravis and bulbar weakness

open access: yesBMC Neurology
Background The present study aimed to develop and validate a nurse-led clinical prediction model for assessing the risk of myasthenic crisis (MC) in myasthenia gravis (MG) patients with bulbar weakness.
Huimin Dong   +3 more
doaj   +1 more source

A case of successful treatment for epilepsy and myasthenia in a young female patient

open access: yesНеврология, нейропсихиатрия, психосоматика, 2016
Epilepsy belongs to the diseases that show the high rate of comorbidity with another abnormality. The complexities of management of patients with two chronic diseases who need continuous treatment are related to the possible impact of therapy for one ...
T. V. Romanova, A. V. Yakunina
doaj   +1 more source

Defining Features of Gabriele‐de Vries Syndrome in Adults: A Case Report and Literature Review

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Gabriele‐de Vries syndrome (GADEVS) is a neurodevelopmental disorder caused by heterozygous pathogenic variants in the YY1 gene. Like most rare genetic syndromes, the adult manifestations of GADEVS remain poorly defined. Here, we describe the oldest patient reported to date with GADEVS—a 63‐year‐old woman with a c.1177_1179del YY1 variant ...
Ethan W. Hollingsworth, Changrui Xiao
wiley   +1 more source

A Myasthenia Gravis Case Diagnosed Simultaneously with Diabetic Ketoacidosis [PDF]

open access: yes, 2019
Juvenile myasthenia gravis (JMG) is an autoimmune disease caused by antibodies affecting the postsynaptic membrane at the neuromuscular junction. The association of JMG with Type I diabetes mellitus (DM), another autoimmune disease, is very rare and the ...
Zehra Aycan   +4 more
core   +1 more source

Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic review and meta-analysis [PDF]

open access: yes, 2023
According to the principle, thymomas combined with myasthenia gravis (MG) require surgical treatment. However, patients with non-MG thymoma rarely develop MG and early- or late-onset MG after surgery is called postoperative MG (PMG).
Gao, Xinliang   +11 more
core   +1 more source

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

open access: yesFrontiers in Immunology, 2021
Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials.
Chiara Agrati   +24 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy